Use your browser's back button to choose another title or click here for a New Search.



How to Get the Article

 Email CTN Library (free)

PubMed Central (free)

Journal subscriber access

 

 Comments?

 

Bookmark and Share

 

From the CTN Special Issue of American Journal of Drug and Alcohol Abuse: Read the other articles here.

 

 

 

Determining the Primary Endpoint for a Stimulant Abuse Trial: Lessons Learned from STRIDE (CTN 0037).

American Journal of Drug and Alcohol Abuse 2011;37(5):339-349. [doi: 10.3109/00952990.2011.598589]

Madhukar H. Trivedi, MD (University of Texas Southwestern Medical Center, TX Node), Tracy L. Greer, PhD (University of Texas Southwestern Medical Center, TX Node), Jennifer Sharpe Potter, PhD, MPH (University of Texas Health Science Center, NEC Node), Bruce D. Grannemann, MA (University of Texas Southwestern Medical Center, TX Node), Edward V. Nunes, MD (New York State Psychiatric Institute, GNY Node), Chad Rethorst, PhD (University of Texas Southwestern Medical Center, TX Node), Diane Warden, MBA (University of Texas Southwestern Medical Center, TX Node), Kolette M. Ring (University of Texas Southwestern Medical Center, TX Node), Eugene C. Somoza, MD, PhD (University of Cincinnati/CinARC, OV Node).

No consensus is available for identifying the best primary outcome for substance use disorder trials, making interpretation across trials difficult. Abstinence is the most desirable treatment outcome although a wide variety of other endpoints have been used. This report provides a framework for determining an optimal primary endpoint and the relevant measurement approach for substance use disorder treatment trials. The framework was developed based on a trial for stimulant abuse using exercise as an augmentation treatment, delivered within the NIDA Clinical Trials Network (protocol CTN-0037). The use of a common endpoint across trials will facilitate comparisons of treatment efficacy. Primary endpoint options in existing substance abuse studies were evaluated. This evaluation included surveys of the literature for endpoints and measurement approaches, followed by assessment of endpoint choices against study design issues, population characteristics, tests of sensitivity, and tests of clinical meaningfulness.

Conclusions: We concluded that the best current choice for a primary endpoint is percent days abstinent, as measured by the Time Line Follow Back interview conducted three times a week with recall aided by a take-home Substance Use Diary. To improve the accuracy of the self-reported drug use, the results of qualitative urine drug screens will be used in conjunction with the Time Line Follow Back results. There is a need for a standardized endpoint in this field to allow for comparison across treatment studies, and we suggest that the recommended candidate endpoint be considered. However, the study design and goals ultimately must guide the final decision. (Article (Peer-Reviewed), PDF, English, 2011)

Keywords: Addiction Severity Index Lite (ASI-Lite) | CTN protocol development | Exercise | Outcomes evaluation | Screening and assessment instruments | Stimulant abuse | Substance Use Diary | Timeline Follow-Back (TLFB) | Urinalysis | Urine Drug Screen (UDS) | American Journal of Drug and Alcohol Abuse (journal)

Document No: 742, PMID: 21854276, PMCID: PMC3274420.

Submitted by CTN Dissemination Librarians, 8/23/2011.

 

AUTHORS SEARCH LINK
Grannemann, Bruce D. mail
Greer, Tracy L. mail
Nunes, Edward V. mail
Potter, Jennifer Sharpe mail
Rethorst, Chad mail
Ring, Kolette M. mail
Somoza, Eugene C. mail
Trivedi, Madhukar H. mail
Warden, Diane mail
PROTOCOLS
NIDA-CTN-0037 www
PARTICIPATING NODES
Texas (Lead) search www
Delaware Valley search www
Florida Node Alliance search www
Greater New York search www
Ohio Valley search www
Southern Consortium search www


dark blue line
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 9/2012 -- http://ctndisseminationlibrary.org/display/742.htm
info@ctndisseminationlibrary.org
dark blue line